Research ArticleNuclear Oncology
Fluorine-18-Fluorodeoxyglucose Assessment of Glucose Metabolism in Bone Tumors
Annemieke C. Kole, Omgo E. Nieweg, Herald J. Hoekstra, James R. van Horn, Heimen Schraffordt Koops and Willem Vaalburg
Journal of Nuclear Medicine May 1998, 39 (5) 810-815;
Annemieke C. Kole
Omgo E. Nieweg
Herald J. Hoekstra
James R. van Horn
Heimen Schraffordt Koops
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Fluorine-18-Fluorodeoxyglucose Assessment of Glucose Metabolism in Bone Tumors
Annemieke C. Kole, Omgo E. Nieweg, Herald J. Hoekstra, James R. van Horn, Heimen Schraffordt Koops, Willem Vaalburg
Journal of Nuclear Medicine May 1998, 39 (5) 810-815;
Jump to section
Related Articles
- No related articles found.
Cited By...
- PET for Sarcomas Other Than Gastrointestinal Stromal Tumors
- PET Imaging of Osteosarcoma
- Prognostic Significance of 18F-FDG and 99mTc-Methylene Diphosphonate Uptake in Primary Osteosarcoma
- The Role of Quantitative 18F-FDG PET Studies for the Differentiation of Malignant and Benign Bone Lesions
- Is There a Role for FDG PET in the Diagnosis of Musculoskeletal Neoplasms?
- Grading of Tumors and Tumorlike Lesions of Bone: Evaluation by FDG PET
- (F-18) Fluorodeoxyglucose Positron Emission Tomography as a Predictor of Pathologic Grade and Other Prognostic Variables in Bone and Soft Tissue Sarcoma